title: Response to ibrutinib in chronic lymphocytic leukemia improves in quality with time.
abstract: Unlike chemoimmunotherapy regimens, which are given for a defined period, ibrutinib, a first-in-class Bruton's kinase inhibitor, allows most patients with CLL to remain on treatment for an extended period. Our experience, supported by sequential CT scan images, suggests that long-term ibrutinib promotes a high response rate that improves in quality with time.
authors.affiliation: Department of Oncology and Hematology "Pugliese-Ciaccio" Hospital viale Pio X Catanzaro 88100 Italy.
authors.forename: Stefano
authors.initials: S
authors.lastname: Molica
authors.affiliation: Department of Oncology and Hematology "Pugliese-Ciaccio" Hospital viale Pio X Catanzaro 88100 Italy.
authors.forename: Guido
authors.initials: G
authors.lastname: Carillio
authors.affiliation: Department of Oncology and Hematology "Pugliese-Ciaccio" Hospital viale Pio X Catanzaro 88100 Italy.
authors.forename: Caterina
authors.initials: C
authors.lastname: Battaglia
keywords: Chronic lymphocytic leukemia; Ibrutinib